Annovis Bio Receives DSMB Approval to Continue Pivotal Phase 3 Alzheimer's Trial
Summary
Annovis Bio announced that its independent Data and Safety Monitoring Board (DSMB) approved the continuation of its pivotal Phase 3 Alzheimer's disease clinical trial for buntanetap, citing no safety concerns at 6 months.
Key Events
-
DSMB Approves Phase 3 AD Trial Continuation
The independent Data and Safety Monitoring Board (DSMB) issued a positive recommendation, supporting the continuation of the pivotal Phase 3 Alzheimer's disease (AD) clinical trial for buntanetap without modification.
-
Positive 6-Month Safety Data
The DSMB concluded that no safety concerns were identified after a comprehensive evaluation of 6-month safety data in Alzheimer's patients, consistent with observations in Parkinson's patients.
-
Potential for Combined Safety Data Submission
The FDA indicated it may consider accepting combined safety data from both the Alzheimer's and Parkinson's studies in a future New Drug Application (NDA) submission.
-
Trial Enrollment 40% Complete
The pivotal Phase 3 AD clinical trial is currently recruiting patients across the United States and is 40% complete, with efficacy readouts anticipated in early 2027 and early 2028.
Analysis
Annovis Bio's receipt of a positive recommendation from the independent Data and Safety Monitoring Board (DSMB) for its pivotal Phase 3 Alzheimer's disease trial is a significant de-risking event. The DSMB's conclusion of no safety concerns at 6 months reinforces confidence in buntanetap's safety profile, allowing the trial to proceed without modification. The FDA's indication that it may consider accepting combined safety data from both Alzheimer's and Parkinson's studies could streamline future regulatory submissions, representing a positive signal for the company's development pathway. This update follows recent positive pipeline updates and confirms the trial's continued progress.
At the time of this filing, ANVS was trading at $2.45 on NYSE in the Life Sciences sector, with a market capitalization of approximately $62.8M. The 52-week trading range was $1.11 to $5.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.